Differential 18F-FDG and 3′-deoxy-3′- 18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models

Abstract

The ability of PET to image functional changes in tumors is increasingly being used to evaluate response and predict clinical benefit to conventional and novel cancer therapies. Although the use of 18F-FDG PET is well established, 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET has potential advantages as a more specific marker of cellular proliferation. c-MET signaling is frequently dysregulated in cancer and is therefore an attractive therapeutic target. Crizotinib (PF-2341066) is a novel adenosine triphosphate - competitive c-MET kinase inhibitor with antitumor activity in a range of tumor models. The aim of this study was to investigate the utility of PET of glucose metabolism and cell pro..